Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News & Events

: Press Releases

Home
News & Events
Press Releases

Press Releases

Tonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored by U.S. Department of Defense

June 15, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference

June 12, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study

May 30, 2017 • 4:30 PM EDT

Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting

May 24, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD

May 22, 2017 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update

May 15, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention

May 11, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use

May 2, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update

April 17, 2017 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option

April 13, 2017 • 11:30 AM EDT

News & Events : Press Releases